News
FTSV
95.51
0.00%
0.00
Webull provides a variety of real-time FTSV stock news. You can receive the latest news about Forty Seven through multiple platforms. This information may help you make smarter investment decisions.
About FTSV
Forty Seven, Inc. is clinical-stage immuno-oncology company. The Company is focused on developing novel checkpoint therapies to activate macrophages in the fight against cancer. The Company’s lead product candidate, 5F9, is a humanized IgG4 subclass monoclonal antibody against CD47 that is designed to interfere with recognition of CD47 by the SIRPa receptor on macrophages. The Company’s another product FSI-189, is an antibody that binds to SIRPa and initiate Phase I solid tumor trials for FSI-189. The Company is investigating 5F9 in multiple Phase I and Phase II trials in various cancers including acute myeloid leukemia (AML), non-Hodgkin's lymphoma (NHL) and colorectal carcinoma (CRC), and ovarian cancer, as both a monotherapy and in combination with other therapies, such as rituximab and cetuximab. In addition to the 5F9, which is an antibody that binds to CD47 blocking its binding to SIRPa.